Investors in Elevance Health (NYSE:ELV) Have Seen Respectable Returns of 31% Over the Past Five Years
Investors in Elevance Health (NYSE:ELV) Have Seen Respectable Returns of 31% Over the Past Five Years
Elevance Health, Inc. (NYSE:ELV) shareholders might be concerned after seeing the share price drop 28% in the last quarter. But the silver lining is the stock is up over five years. In that time, it is up 23%, which isn't bad, but is below the market return of 95%.
Elevance Health, Inc. (紐交所:ELV) 的股東可能會對此感到擔憂,因爲在過去一個季度中,股價下跌了28%。不過,令人欣慰的是,這隻股票在過去五年中上漲了。在這段時間內,它上漲了23%,雖然這並不差,但低於市場回報的95%。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
讓我們看看更長期的基本面,看看它們是否與股東回報一致。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
雖然市場是一個強大的定價機制,但股價反映的卻是投資者情緒,而不僅僅是基礎業務表現。一種不完美但簡單的考慮收入每股收益(EPS)變化與股價變動的市場認知變化的方法是比較它們之間的差異。
Over half a decade, Elevance Health managed to grow its earnings per share at 11% a year. This EPS growth is higher than the 4% average annual increase in the share price. Therefore, it seems the market has become relatively pessimistic about the company.
在過去五年中,Elevance Health成功地將每股收益以每年11%的速度增長。這個每股收益的增長高於股價的平均每年4%的增長。因此,市場似乎對該公司變得相對悲觀。
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
您可以在下面看到EPS如何隨時間變化(點擊圖片可以發現具體數值)。
Dive deeper into Elevance Health's key metrics by checking this interactive graph of Elevance Health's earnings, revenue and cash flow.
通過查看Elevance Health的收益、營業收入和現金流的互動圖表,深入了解Elevance Health的關鍵指標。
What About Dividends?
關於分紅派息的問題
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Elevance Health the TSR over the last 5 years was 31%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence!
投資者在衡量股價回報的同時,也應該考慮總體股東回報(TSR)。股價回報只反映股價的變化,而TSR則包括分紅的價值(假設它們被再投資)以及任何折扣資本融資或剝離的利益。因此,對於支付豐厚分紅的公司來說,TSR通常比股價回報高得多。我們注意到,Elevance Health在過去5年的TSR爲31%,這比上述股價回報要好。而且,毫無疑問,分紅派息的支付很大程度上解釋了這種差異!
A Different Perspective
不同的視角
Elevance Health shareholders are down 21% for the year (even including dividends), but the market itself is up 24%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 5% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Elevance Health is showing 2 warning signs in our investment analysis , you should know about...
Elevance Health的股東今年虧損21%(即使包括分紅),但市場本身上漲了24%。然而,請記住,即使是表現最好的股票,有時也會在12個月的時間內跑輸市場。好消息是,長揸的股東獲得了收益,在過去五年中每年增長5%。最近的拋售可能是個機會,因此值得檢查基本數據以尋找長期增長趨勢的跡象。我發現長期股票價格作爲業務表現的代理指標非常有趣。但爲了真正獲得見解,我們還需要考慮其他信息。即便如此,要注意Elevance Health在我們的投資分析中顯示出2個警告信號,您應該了解...
But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:Elevance Health 可能不是最好的購買股票。因此,請查看這份關於過去盈利增長(以及未來增長預期)的有趣公司的免費名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。
譯文內容由第三人軟體翻譯。